New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 16, 2014
07:00 EDTCNCEConcert Pharmaceuticals says FDA lifts partial clinical hold for CTP-354
Concert Pharmaceuticals announced that the FDA has provided notification that the company has completed the necessary preclinical toxicology testing in order to administer repeated doses of CTP-354 in excess of 6 mg per day, lifting its partial clinical hold. As a result, the company intends to initiate dosing of 12 mg per day of CTP-354 in the third quarter of this year as part of its ongoing multiple ascending dose Phase 1 trial. Concert is initially developing CTP-354 for use in patients with spinal cord injury and in patients with multiple sclerosis to address significant unmet medical needs.
News For CNCE From The Last 14 Days
Check below for free stories on CNCE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 12, 2014
16:12 EDTCNCEBiotechnology Value Fund reports 6.7% passive stake in Concert Pharmaceuticals

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use